Researchers have identified obesity-related changes in lipid metabolism that may contribute to the development and progression of Alzheimer’s disease (AD), according to a study published in Molecular Neurodegeneration.
The study focused on phosphatidylethanolamine (PE), a lipid involved in cell membrane structure and cellular signaling. Using lipidomics, single-nucleus RNA sequencing, proteomics, and imaging analyses, investigators examined how obesity-associated metabolic changes affect communication between immune cells and neurons in the brain.
The researchers found that obesity was associated with increased PE accumulation in peripheral tissues and the brain. This imbalance was linked to disrupted immune signaling, abnormal lipid droplet buildup in brain tissue, impaired T-cell activity, altered microglial function, and increased amyloid-related pathology in neurons. The findings suggest that obesity-related metabolic dysfunction may impair neuroimmune communication and accelerate processes associated with AD.
The work was performed primarily in mouse models of AD and included both behavioral and molecular analyses. The authors reported that altered membrane lipid composition appeared to affect signaling pathways between immune and neural cells.
Investigators also evaluated whether targeting PE dysregulation could modify these effects. Treatment with ebselen, a redox-active compound, reduced some lipid abnormalities and was associated with partial improvement in neuroimmune signaling and cognitive performance in the experimental models.
The study highlights the growing role of lipidomics and multi-omics technologies in neurodegenerative disease research. Current AD diagnostics primarily focus on amyloid and tau biomarkers measured through cerebrospinal fluid analysis, imaging, and emerging blood-based assays. The authors suggest that obesity-associated lipid signatures may represent an additional area for future biomarker research.
The analytical workflow included liquid chromatography–mass spectrometry–based lipidomics, reflecting the increasing use of advanced laboratory technologies to study mechanisms of neurodegeneration.
The findings also add to existing evidence linking metabolic disorders with dementia risk. Although obesity has previously been associated with increased AD risk, the biological mechanisms connecting metabolic dysfunction to neurodegeneration have remained incompletely understood.
The authors noted that further studies will be needed to determine whether PE-related lipid alterations could eventually support biomarker development or therapeutic monitoring in clinical settings. They emphasized that the current findings require validation in human studies.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
